💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Canagliflozin Anhydrous

CHEMBL2048484 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
444.5 g/mol
LogP
3.2
Phase
4

The anhydrous form of canagliflozin, an SGLT2 inhibitor used for blood sugar management in type 2 diabetes with additional cardiovascular and renal benefits. This non-hydrated salt form is used in specific pharmaceutical formulations for stability. It shares the same mechanism and clinical profile as the standard canagliflozin formulation.

น้ำหนักโมเลกุล

444.5000 g/mol

LogP

3.20

TPSA

118.00 Ų

Lipinski RO5

ผ่าน

กลไกการออกฤทธิ์

Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1

                

                

                
                

                    
InChI

                    
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H25FO5S

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
พันธะที่หมุนได้

                        
5

                    

                    
                    
                    

                        
อะตอมหนัก

                        
31

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
The anhydrous form of canagliflozin, an SGLT2 inhibitor used for blood sugar management in type 2 diabetes with additional cardiovascular and renal benefits. This non-hydrated salt form is used in specific pharmaceutical formulations for stability. It shares the same mechanism and clinical profile as the standard canagliflozin formulation.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Canagliflozin Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2048484.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 24812758.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.